CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BridgeBio Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BridgeBio Pharma Inc
421 Kipling St
Phone: (650) 391-9740p:650 391-9740 PALO ALTO, CA  94301-1530  United States Ticker: BBIOBBIO

Business Summary
BridgeBio Pharma, Inc. is discovering and developing medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-265, BBP-831, BBP-631 and BBP-454.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202012/31/2019YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Director NeilKumar 41 4/1/2015 4/1/2015
Chief Financial Officer Brian C.Stephenson 39 10/1/2018 10/1/2018
Chairman of Pharmaceuticals, Lead Director Charles J.Homcy 71 2/1/2020 11/1/2018
11 additional Officers and Directors records available in full report.

Business Names
Business Name
Adrenas Therapeutics, Inc.
Aspa Therapeutics, Inc.
Audition Therapeutics, Inc.
24 additional Business Names available in full report.

General Information
Number of Employees: 296 (As of 3/31/2020)
Outstanding Shares: 121,369,992 (As of 5/8/2020)
Shareholders: 27
Stock Exchange: NASD
Fax Number: (302) 655-5049


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 11, 2020